QuantRx Biomedical

About QuantRx Biomedical

The story of QuantRx Biomedical is one of shifting focus in the competitive diagnostics landscape. The company originally aimed to develop and commercialize advanced diagnostic and therapeutic products. A key figure in its journey was Stephen M. Simes, who served as Chairman, President, and CEO. The company's focus was on areas like reproductive health and infectious diseases, developing platforms for rapid diagnostic testing. QuantRx operated as a publicly traded company, listed under the ticker QTRX. This status as a public entity meant its financials and corporate actions were subject to public scrutiny and market pressures. The company's journey involved navigating the complex regulatory pathways for medical devices and diagnostics, a challenging feat for any player in the biomedical field. A significant turning point for QuantRx was its decision to cease active business operations. In 2013, the company filed a Form 15 with the SEC to terminate the registration of its securities. Following this, QuantRx entered into an Asset Purchase Agreement with Aelia LLC, leading to the transfer of its assets, including its Aelia brand of cosmeceuticals and nutraceuticals, to a new entity. This move marked a definitive pivot away from its original mission in the diagnostics sector and the end of its chapter as an active public company, with its assets continuing under the Aelia name.